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Abstract
The available therapy against Helicobacter pylori is based on a combination of antibiot-
ics and proton pump inhibitors. The high prevalence of antibiotic-resistant strains leads 
to failure of this complex therapeutic regimen, leaving millions of people worldwide 
without effective therapeutic options. “Nature-derived” bioactive compounds with anti-
bacterial performance may be of value for developing newer and more effective strate-
gies. For centuries, natural compounds have played a pivotal role in traditional medicine 
and, in the last decades, they have gained renewed strength in the clinical field, boosted 
by advances in chemical characterization and extensive activity screening. Also, their 
recognition in gastric infection management has been empowered by the bioengineering 
field, namely by the development of stomach-specific delivery strategies. In this chapter, 
natural bioactive compounds, such as polyunsaturated fatty acids and triterpenic acids 
with anti-H. pylori effect, are described. The bioengineering approaches used to overcome 
their limited intrinsic bioavailability are briefly highlighted.
Keywords: nanotechnology, bioactive compounds, lipophilic compounds, 
phytochemicals, antibiotic-free therapies
1. Introduction
Helicobacter pylori is the etiologic agent of several gastric disorders that may range from 
chronic gastritis to more severe outcomes [1]. Ultimately, the complex interplay between 
H. pylori, the host susceptibility, and environmental factors such as smoking and drinking 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
can lead to gastric cancer, which is the fifth most common cancer worldwide, accounting for 
754,000 deaths in 2015 [2, 3]. Despite significant medical advances, the 5-year survival rate 
from gastric cancer is low (31%), mainly because this cancer is diagnosed at later stages [4]. It 
is widely recognized that the best strategy to reduce the risk of gastric carcinoma associated 
with H. pylori infection is its eradication from infected hosts [5, 6]. The current treatment relies 
on a combination of antibiotics (clarithromycin plus amoxicillin or metronidazole) and an 
acid-suppressive drug (e.g., proton-pump inhibitor), since no available substances are effec-
tive as monotherapy [7]. However, the eradication rates of this therapeutic scheme have been 
declining to unacceptable levels [8], mostly due to high antibiotic resistance levels. In fact, 
H. pylori has been placed among the 16 antibiotic-resistant bacteria that pose greatest threat 
to human health [9]. It is noteworthy that besides resistance and coinfection with multiple 
strains with distinct antibiotic susceptibilities, other factors also account for conventional 
treatment failure:
a. drugs bioavailability: antibiotics are typically administrated via the oral route. Since the 
gastric mucus layer acts as a barrier to antibiotic delivery, most drugs are unable to reach 
the underlying gastric epithelium, where H. pylori is attached [10];
b. gastric features: the pH at the stomach/duodenum varies from acidic to neutral, depend-
ing on the presence or absence of food and the location within the mucus barrier that cov-
ers the epithelial cells. This affects the efficacy of most antibiotics once only a few remain 
active in a wide pH range [11–13];
c. compliance: side effects, such as taste disturbances with clarithromycin and metronida-
zole, and diarrhea with amoxicillin, account for the poor patient compliance. Additionally, 
complex regimens that require multiple doses of medication each day also decrease thera-
peutic compliance [14];
d. lifestyle: smoking and alcohol consumption are thought to contribute for treatment 
failure [15].
In this scenario, where H. pylori traditional antibiotic therapies fail, a considerable inter-
est in alternative therapeutic players combined with bioengineering strategies has arisen. 
Several “nature-derived” options have been studied [5], and some of them are summarized 
in Figure 1.
Although very promising in vitro, these molecules share a common drawback when trans-
ferred to in vivo settings: intrinsic limited bioavailability. Figure 2 summarizes some of the 
bioengineering approaches envisioned to overcome the mentioned limitation.
Chitosan micro-/nanoparticles have been extensively studied as drug delivery systems tar-
geting H. pylori infection [16], mainly due to its gastric retentive properties [17]. Chitosan, a 
natural biocompatible polysaccharide obtained by N-deacetylation of chitin [18], has muco-
adhesive properties due to electrostatic interactions between its cationic amine groups and 
gastric mucins, which are negatively charged at the acidic gastric pH [19, 20].
Chitosan microspheres were used to encapsulate and improve the biological activity of trans-
resveratrol, a phenolic compound that has, among other biological activities, anti-H. pylori 
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action [21]. Polyelectrolyte complex nanoparticles (PNPs), prepared by the combination 
of chitosan with negatively charged polymers, alginate or heparin, have also been used to 
encapsulate the antimicrobial peptide pexiganan [22] and berberine [23], respectively. This 
approach increased the effectiveness of these bioactive compounds, inhibiting H. pylori growth 
and reducing their cytotoxic effects.
Figure 1. Some “nature-derived” bioactive compounds described in the literature in the scope of novel anti-H. pylori 
therapeutics.
Figure 2. Most common bioengineering approaches applicable to “nature-derived” bioactives in the scope of H. pylori 
infection management.
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Other strategies that can be used to overcome the low bioavailability and solubility of lipo-
philic compounds comprise ionic liquids (IL) and lipid nanoparticles.
IL are a new class of powerful catanionic hydrotropes, where both the cation and the anion 
synergistically contribute to increase the solubility of biomolecules in water [24]. Therefore, 
IL enhance the solubility of hydrophobic substances in aqueous media and are widely used 
in the formulation of drugs, cleaning, and personal care products. IL have been explored to 
increase the water solubility of triterpenic acids, such as of betulinic acid [25, 26].
Lipid nanoparticles are very useful to encapsulate lipophilic compounds due to their higher 
biocompatibility compared to polymeric nanoparticles [27, 28]. Liposomes, firstly described 
in the mid-1960s, are sphere-shaped vesicles consisting of one or more phospholipid bilayers. 
Liposomes are the first nanodrug delivery systems that have been successfully translated into 
real-time clinical application [29–31]. Nanostructured lipid carriers (NLCs) are lipid nanopar-
ticles specifically designed and patented as drug delivery systems, and they are character-
ized by a solid-lipid core composed of a mixture of solid and liquid lipids [32]. NLCs can be 
prepared using a wide variety of lipids including fatty acids, glyceride mixtures, or waxes, 
stabilized with biocompatible surfactants, which makes this a very versatile strategy. Both 
are considered safe and under the Generally Recognized as Safe (GRAS) status issued by the 
Food and Drug Administration (FDA) [31, 33].
Polyunsaturated fatty acids and triterpenic acids with anti-H. pylori effect have gained 
renewed interest in the scientific community as alternatives to overcome the increasing num-
ber of drug-resistant bacteria. These lipophilic bioactive compounds can largely benefit from 
a nanotechnological approach to improve their stability and to overcome their limited intrin-
sic bioavailability and thus, they will be briefly highlighted in the next sections.
2. “Nature-derived” anti-H. pylori fatty acids
Free fatty acids, also known as antimicrobial lipids [34], are linear carbon chains, which 
are the main constituent of phospholipids, triglycerides, sterol esters, among others [35]. 
Consequently, they are important for biological activities, such as for energetic, metabolic, and 
structural processes [35]. Fatty acids are classified according to the length of the carbon chains, 
the number of double bonds, and their positions within the moiety [35]. Polyunsaturated fatty 
acids (PUFAs) have two or more double bonds [36], and they have been recognized for their 
broad-spectrum activity against bacteria (e.g., H. pylori), fungi, protozoa, and virus [36–38]. 
This is due to the ability of fatty acids to work as mild surfactants [34]. The disturbance of 
the bacterial cell membrane can lead to the deregulation of metabolic pathways, inhibiting 
the bacterial growth, or even to lysis and death [34]. The specific interaction between anti-
microbial fatty acids and bacterial membranes remains to be fully understood. Some studies 
revealed that free fatty acids can induce different kinds of morphological changes in the mem-
brane [39, 40]. Khulusi et al. and Correia et al. reported that fatty acids can be incorporated 
into H. pylori phospholipids membrane, being able to change the bacillary morphology of 
the bacteria to their coccoid shape [32, 41–43]. Several studies also identified the bacterial 
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membrane as the main target of fatty acids, leading to a sequence of biophysical phenomena 
including membrane destabilization, pore formation, and lysis of bacteria [32, 41, 44, 45]. The 
multiple mechanisms that are behind their ability to perturb bacterial cell membranes lead to 
a low probability of antimicrobial resistance [34]. On the opposite, small molecules, such as 
commercial antibiotics, inhibit specific enzymes and, consequently, increase the probability of 
antimicrobial resistance development [34].
The antibacterial activity of PUFAs depends on their molecular structure. In fact, the existence 
of double bonds and, more specifically, their number and orientation within the fatty acids 
are important for their physicochemical properties [46, 47]. These structural differences are 
reported to affect their ability to inhibit H. pylori growth in vitro [45]. For instance, the inhibi-
tory effect is higher for higher degrees of unsaturation: [oleic (C18:1) < linoleic (C18:2) < ara-
chidonic (C20:4) < n-3 linolenic (C18:3) = n-6 linolenic (C18:3) = eicosapentaenoic (C20:5) acid] 
[45]. The encapsulation of free fatty acids in nanoparticles can improve their pharmacokinetic 
and pharmacological properties [34]. A review of the nanotechnology formulations used to 
encapsulate antimicrobial lipids was recently published [34].
In this section, two of the most promising fatty acids (docosahexaenoic acid (DHA) and lino-
lenic acid (LA)) are described regarding their specific application against H. pylori.
Figure 3 illustrates the two bioengineering approaches that have been applied to DHA and 
LA that will be discussed in the following subsections.
2.1. Docosahexaenoic acid (DHA)
DHA inhibits H. pylori growth both in vitro and in vivo, since it is able to reduce H pylori adhe-
sion to gastric cells and bacterial ATP production [42, 43, 48]. DHA induces changes in expres-
sion of H. pylori outer membrane proteins associated with stress response, metabolism, and 
modified bacterial lipopolysaccharide phenotype [43]. DHA is also able to indirectly interfere 
with H. pylori growth since it alters cholesterol levels in epithelial cells, thereby influencing 
the bacterium ability to uptake and use epithelial cholesterol [48].
Figure 3. Encapsulation of fatty acids, namely DHA and LA, in different types of nanoparticles.
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Although in vivo studies using gastric-infected mice demonstrated that DHA was able to 
decrease only 50% of H. pylori gastric colonization, the DHA conjugation with antibiotic stan-
dard treatment decreased the recurrence of H. pylori infection [42, 43].
Another DHA feature is its ability to attenuate the host inflammatory response associated 
with gastric infection [49, 50].
DHA poor solubility in water, fast oxidation/degradation plus gastric settings drawbacks 
(namely low gastric residence time and low penetration through the gastric mucus layer) are 
challenging issues for its clinical translation [36, 50, 51]. To overcome these obstacles, cyto-
compatible lipid nanoparticles have been researched to encapsulate DHA [44, 52]. It was dem-
onstrated that DHA lipid nanoparticles are able to destabilize H. pylori membranes, leading to 
disruption and leakage of cytoplasmic contents [32, 44]. Importantly, these lipid nanoparticles 
do not interfere with normal gut microbiota in opposite to dramatic changes described for the 
conventional antibiotic therapy [44].
2.2. Linolenic acid (LA)
LA, as fatty acids in general, is considered safe [53]. It is classified as an essential fatty acid, 
once it cannot be synthesized by the human body, being necessary to be supplied by the 
diet [54]. Its importance for biological processes is unquestionable. LA undergoes metabolic 
changes in vivo that ultimately lead to the formation of prostaglandins, thromboxanes, leu-
kotrienes, and lipoxins [54]. Furthermore, the usefulness of LA as an antibacterial agent was 
also proved, being one of the most potent unsaturated fatty acids against H. pylori [7]. It also 
promotes the adhesion of Lactobacillus casei to mucosa surfaces, which indirectly hinders the 
growth of H. pylori [55]. Besides its bactericidal effect, LA is also important for the integrity 
of the gastric mucosa. It was already proposed that lower levels of essential fatty acids, such 
as LA, lead to decreased levels of prostaglandins and, consequently, to a higher susceptibility 
of the gastric mucosa to ulcerogenic agents [56].
Nanotechnology has been successfully used to load fatty acids, including LA [34]. As above 
mentioned, the oral administration of fatty acids is hindered by their poor solubility, espe-
cially at acidic pH, and their susceptibility to chemical degradation [57]. In fact, the carboxyl 
protonation under acidic pH at the stomach lumen decreases the efficacy of fatty acids 
after oral administration [53]. This was already shown in vivo, with no significant effect of 
plain LA in killing H. pylori on a mouse model [53]. Nevertheless, liposomes are promising 
bioengineering strategies to overcome these limitations. Due to the amphiphilic nature of 
fatty acids, they can be easily incorporated into the phospholipid bilayer of liposomes [57]. 
Hence, Obonyo et al. used liposomes of egg phosphatidylcholines, cholesterol, and LA to kill 
H. pylori [57]. They showed that LA-loaded liposomes were effective against H. pylori even 
in its coccoid form and regardless their resistance to antibiotics [57]. Interestingly, H. pylori 
developed resistance against free LA at subbactericidal concentrations, whereas it showed no 
resistance against LA when incorporated into the nanoparticles [57]. These results show the 
promising usefulness of nanotechnology not only to protect the fatty acid from its degrada-
tion, but also to improve its efficacy. The higher efficacy relies on their ability to fuse with the 
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bacterial membrane, being directly and faster incorporated into the bacterial membrane [57]. 
Their main mechanism is the increase of the permeability of the outer membrane and of the 
plasma membrane of H. pylori, which leads to a leakage of cytoplasmic contents [58]. They 
also decrease the H. pylori-induced proinflammatory cytokines, helping in the healing of the 
gastric mucosa [58]. Furthermore, the ability of those liposomes to be retained at the site of 
infection was also shown in vivo [53]. The retention for up to 24 h was attributed to the small 
size of the liposomes and their anionic surface charge, which decreases their hydrophobic 
entrapment [53]. The biocompatibility of the formulation was shown through gastric histopa-
thology and mucosal integrity and by the maintenance of the gut microbiota, on the opposite 
of the current triple therapy [53, 59].
3. “Nature-derived” anti-H. pylori phytochemicals
Phytochemicals have been used for centuries in the treatment of gastrointestinal disorders, 
such as dyspepsia, gastritis, and peptic ulcer disease [60]. Over the last two decades, phyto-
therapy has gained strength in the scientific community, prompted by the need of alternatives 
to the ineffectiveness of traditional antibiotics.
Plants synthesize a vast range of secondary metabolites with a significant portion consisting of 
phenolic and flavonoid compounds [61]. These secondary metabolites, other than providing 
plants with unique survival or adaptive strategies, are associated to a wide range of biological 
activities [62]. Phenolic compounds, namely wine polyphenols, from which resveratrol is the 
most studied, and olive oil polyphenols, mainly hydroxytyrosol, have been associated with 
anti-H. pylori activity [5]. Lipophilic compounds from the terpenes family can also be obtained 
from several plants. In the scope of anti-H. pylori strategies, these are described in more detail 
in the following section.
3.1. Triterpenic acids














), where n is the number of isoprene units. Depending on the number 
of isoprene building blocks, they are classified into several groups, such as monoterpenes, 
sesquiterpenes, diterpenes, triterpenes, and tetraterpenes (with 2, 3, 4, 6, and 8 isoprene units, 
respectively). These compounds can undergo chemical modifications by oxidation or rear-
rangement of the carbon skeleton, which leads to a vast group of compounds denominated 
terpenoids [63].
Pentacyclic triterpenoids are commonly isolated as active substances from different natu-
ral sources, mainly plant surfaces such as stem bark or leaf and fruit waxes [64]. Among 




) are being marketed as therapeutic agents or dietary 
supplements around the world due to their biological applications [65, 66]. Their antibacte-
rial properties are also recognized. For instance, it was demonstrated that the acidic fraction 
of the total mastic extract without polymer (TMEWP) from the Chios Mastic Gum (resin of 
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Pistacia lentiscus var. chia) is effective in killing H. pylori [67]. This antibacterial effect was 
attributed to their rich composition in oleanolic acid, isomasticadienolic acid, masticadieno-
lic, and moronic acid [67]. Paraschos et al. demonstrated that the prophylactic treatment with 
the TMEWP was not able to prevent H. pylori infection in C57BL/6 mice infected with mouse-
adapted H. pylori SS1 strain [67]. Nevertheless, the number of H. pylori colonies significantly 
reduced (1.5 log colony forming units/g of tissue) when the animals were subjected to con-
tinuous administration of 0.75 mg of TMEWP for 3 months [67]. Shin et al. reported that betu-
linic acid and oleanolic acid, extracted from Fosythia suspensa, were able to inhibit the urease 
activity of H. pylori ATCC 43504 [68]. Furthermore, Parreira et al. reported that outer bark 
extracts of Eucalyptus nitens and E. globulus, rich in betulinic, betulonic, oleanolic, and ursolic 
acids (Figure 4), have anti-H. pylori activity against strains with distinct virulence degree [69]. 
Interestingly, the eucalyptus extracts had a lower minimal inhibitory concentration than the 
isolated pure triterpenic acids, which led to the conclusion that the final observed antibacte-
rial effect was due to synergic effects [69].
Although not specifically designed toward H. pylori infection, different strategies to improve 
the oral bioavailability of triterpenic acids have been studied. For example, oleanolic acid bio-
availability has been enhanced by using a phospholipids complex with hydroxyapatite [70]. 
Yang et al. have developed liposomes to increase ursolic acid bioavaliabitliy [71] and pharma-
cokinetic studies carried out by Ge et al. reported that the oral bioavailability of ursolic acid 
was 27.5-fold higher when it was incorporated in nanoparticles than when administered as a 
free compound [72].
The abovementioned advances in increasing the bioavailability of triterpenic acids using 
bioengineering strategies will enable, in the near future, to further pursue research of novel 
nonantibiotic and more effective “nature-inspired” therapies against H. pylori.
Figure 4. Chemical structures of triterpenic acids: betulinic (BA), betulonic (BOA), oleanolic (OA), and ursolic (UA) acids.
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4. Translation to real-world scenario
Both fatty acids and triterpenic acids have been reported to exhibit similar performance 
against H. pylori. Nevertheless, their action mechanisms are fairly distinct: while fatty acids 
are reported to interact with the bacterial membrane, triterpenic acids are reported to be more 
involved in enzymatic inhibition, namely urease hindering [5]. Since both bioactives classes 
target crucial structures for H. pylori survival, emergence of resistance is not anticipated, as it 
would require massive bacterial energy [32, 69].
Despite the remarkable effects associated to fatty and triterpenic acids for gastric infection man-
agement, translation into real-world applications is still delayed. For that, it has contributed the 
fact that only in the last decade more attention has been paid to nature-derived molecules, coun-
teracting the “chemical pharmacological” tendency that had been initiated in the beginning of 
the twentieth century. Also, there was a significant reduction of investment in the clinical devel-
opment of antibiotics over the last years. In fact, only 1.6% of the drugs under clinical develop-
ment by the world’s largest drug companies are antibiotics [73]. This has boosted the search for 
other sources of antimicrobials. In addition, bioengineering emerged in the twenty-first century 
as a powerful tool to develop drug delivery systems and, consequently, to overcome the more 
generalized drawbacks associated with the lipophilic bioactive compounds discussed in this 
chapter [5]. Bioengineering approaches for fatty acids specific application against H. pylori 
are already on a “fast-track,” while those for triterpenic acids are only now evolving, which 
explains the lack of solid studies coupling these bioactives with bioengineering strategies.
To the date and to the best of our knowledge, most of the herein described compounds are 
in in vivo studies phase, being expected that in the next few years some will cross the clinical 
trials barrier. There are several factors contributing to the anticipated success of these “nature-
based” strategies. They are generally cost-effective, due to their abundance in nature, and 
they require low-cost extraction productions. Furthermore, the biotechnological improve-
ments that include nanotechnological coupling to nature-derived molecules will hopefully 
contribute to reaching “real-life” applications. In addition, more “nature-based” molecules 
are reaching the market with FDA approval to treat infectious disease, such as antimalaria 
Artemisinin therapies, based on an herb employed in Chinese traditional medicine [74], 
which anticipates the future success of nature-inspired strategies for H. pylori eradication.
5. Conclusion
H. pylori infection is one of the most prevalent infections worldwide, which is also reflected onto 
the high prevalence of gastric cancer. Emerging antibiotic resistance leads to an urgent need of 
alternative treatments. Resourcing to widely available lipophilic natural bioactive compounds 
with anti-H. pylori activity, namely fatty or triterpenic acids, should be further considered as novel 
therapeutic options. In this context, nanotechnology emerges as a key player, as it allows overcom-
ing the bioactive major drawbacks that have been holding back their “real-world” application.
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